Accelerate your project, cut costs, and gain access to expert phage display scientists by outsourcing your lab with us. With the rapid growth of the therapeutic peptide and antibody markets, phage display is becoming an increasingly valuable method. Yet, finding expert scientists in this field can be challenging and time-consuming. By partnering with us, you can focus on your core objectives while we ensure your phage display projects are handled by our seasoned team of experts.
In today's fast-paced research environment, companies are often faced with critical decisions about resource allocation and expertise requirements. Outsourcing your phage display laboratory needs to Cell Origins presents a strategic advantage that can streamline your research efforts and enhance productivity. By collaborating with industry experts, you leverage specialized knowledge and state-of-the-art technology without the overhead costs associated with hiring and maintaining an in-house phage scientist.
Outsourcing your phage display needs allows your team to focus on core competencies while gaining access to a wealth of experience and innovative methodologies that can significantly accelerate your research timelines. Our dedicated team not only provides reliable and reproducible results but also ensures compliance with the latest regulations and standards, further reducing the risks inherent in research activities. Choose Cell Origins as your outsourcing partner and empower your organization to achieve remarkable scientific results while optimizing resource efficiency.
Our expert team of scientists at Cell Origins are specialists in phage display technology. With decades of experience and a passion for innovation, our scientists are dedicated to helping researchers achieve their goals in peptide and antibody discovery. Trained at the University of Missouri, the birthplace of phage display, our lead scientists have significantly contributed to the field. Their work has been cited in the Nobel Prize lecture by awardee Dr. George Smith, highlighting our commitment to excellence and advancement in phage display research.
At Cell Origins, our expertise spans nearly 40 years in the development of cutting-edge strategies for phage display, peptide and antibody discovery, and ligand optimization. With a team of industry-leading experts in phage display and drug discovery, we are dedicated to ensuring the success of your project. Our comprehensive services include:
We provide a wide range of consultancy services such as comprehensive customized research strategies and protocols, enabling the selection of high-affinity peptides and antibodies with exceptional pharmacokinetic profiles . Additionally, we offer expert guidance on lead optimization, enhancing binding kinetics, off-target binding profiles, and tissue excretion redirection for your existing peptides and antibodies. Our research strategies have contributed to numerous impactful publications, projects, and research grants. Learn more here.
At Cell Origins, we address the challenge of generating peptides and antibodies with exceptional binding affinity and pharmacokinetic properties using our MultiTier phage display platform . Our platform utilizes a unique combination of in vitro, in situ, and in vivo screening methods along with advanced automated high-throughput sequencing technologies and in silico analysis to identify high-quality peptides and antibodies. Learn more here.
Following phage display affinity selections, peptides and antibodies are screened using biomolecular interaction analysis to identify the best leads. Various methods such as peptide- and antibody-arrays, ELISA, AlphaLISA, SPR, and DLS are used for this analysis. Cell Origins develops customized protocols to ensure optimal lead identification, often incorporating cell and tissue analyses.
While phage display affinity selections are efficient, the screening of selected peptides and antibodies is often a bottleneck due to the time-consuming and costly synthesis, production, and purification processes. Furthermore, the limited stability of soluble peptides and antibodies during storage complicates screening and increases experimental costs. To overcome this hurdle, we also provide high-throughput screening of ligand-displaying phage particles to accelerate production while reducing costs and time. Additionally, this screening significantly enhances signal amplification compared to conventional biomolecular interaction analysis methods like ELISA. Learn more here.
We conduct lead optimization, including affinity maturation of peptides and antibodies, to enhance binding affinity, specificity, stability, and biodistribution of initial lead molecules. This can be achieved through the optimization and screening of soluble peptides and antibodies or by generating sub-phage display libraries for high-throughput optimization.
At Cell Origins, we recognize that establishing a new phage lab and integrating new personnel can be a complex undertaking. Our team is here to facilitate a smooth onboarding process, guiding your new hires through the essentials of phage display technology. We offer comprehensive training programs that equip your staff with the necessary skills and knowledge to operate effectively within your new lab environment.
Moreover, Cell Origins provides expert consultation for setting up your phage lab, ensuring that you have the right equipment, protocols, and systems in place to maximize productivity from day one. Our tailored solutions include practical demonstrations and technical resources which help to instill confidence and competence in your staff.
In addition to initial onboarding, our commitment to your success extends into ongoing technical phage display support. Cell Origins delivers continuous assistance through regular consultations, troubleshooting, and updates on the latest advancements in phage technology. With our extensive experience, we can address challenges your team may encounter, enabling them to focus on their research without distraction. By choosing Cell Origins, you not only gain a partner in setting up your lab but also a resource for sustaining your research excellence over time.
At Cell Origins, we prioritize the confidentiality of your research and proprietary information. We understand that trust is fundamental in fostering productive partnerships. That’s why we are more than willing to sign a confidentiality agreement, ensuring that your sensitive data remains protected throughout our collaboration. Moreover, we do not take a cut of commercialization licenses, allowing you to retain full ownership and control over your innovations. With Cell Origins as your partner, you can focus on advancing your research without concern for the security of your intellectual property.
The founders of Cell Origins received their training at the University of Missouri, where phage display technology was pioneered. Our scientists have published numerous research articles, including ones cited by Dr. George Smith in his Nobel Prize lecture. Our team of scientists leverages cutting-edge approaches to unlock the full potential of phage display, ensuring success for your research project.
We are a contract research organization and development company with a proven track record in the field of phage display. Let our experienced team help you develop a strategy that optimizes results and provides the best solution for your research needs.
At our core, we are dedicated to delivering excellent service that guarantees the success of your project. To begin this journey, please schedule a consultation so we can learn more about your research requirements and how we can assist you. Our commitment lies in aiding you to receive the most effective solution for your project, propelling your research process forward. Reach out to us today to expand your horizons and schedule a meeting with one of our experienced scientists.
Ongoing support for your discovery team
Essential tools to kick start your phage display project
One fulltime equivalent phage display expert
Discovery team of three fulltime phage display experts
Asar M, Newton-Northup J, Soendergaard M. (2024). Improving Pharmacokinetics of Peptides Using Phage Display. Viruses. 16(4):570. doi: 10.3390/v16040570.
Axiak-Bechtel SM, Leach SB, Newton-Northup JR, Milner RJ, Fox-Alvarez SA, Fagman LI, Young KA, Tate DJ, Wright ZM, Chretin JD, Allen JW, Yoshimoto SK, Selting KA, Flesner BK, White CR, Mills T, Aherne M, Bergman PJ, Qi L, Gruber KA, Callahan MF. (2023). Safety of TCMCB07, a melanocortin-4 antagonist peptide, in dogs with naturally occurring cachexia. J Vet Intern Med. 37(6):2344-2355. doi: 10.1111/jvim.16915.
Gruber KA, Ji RL, Gallazzi F, Jiang S, Van Doren SR, Tao YX, Newton Northup J. (2022). Development of a Therapeutic Peptide for Cachexia Suggests a Platform Approach for Drug-like Peptides. ACS Pharmacol Transl Sci. 5(5):344-361. doi: 10.1021/acsptsci.1c00270.
Axiak-Bechtel, S. M., Leach, S. B., Scholten, D. G., Newton-Northup, J. R., Johnson, B. J., Durham, H. E., Gruber, K. A., Callahan, M. F. (2021). Pharmacokinetics and safety of TCMCB07, a melanocortin-4 antagonist peptide in dogs. Pharmacology Research & Perspectives. Vol. 9(3)
Asar, M., Franco, A., Soendergaard, M. (2020). Phage Display Selection, Identification, and Characterization of Novel Pancreatic Cancer Targeting Peptides. Biomolecules. 10(5), 714
Asar, M., Gunby, T., Franco, A., Woodson, C., Soendergaard, Mette. (2020). Identification of an Indiscriminate Peptide by Phage Display Technology. The FASEB Journal 34:1_supplement, 1-1
Asar, M., Newton-Northup, J., Deutscher, S., Soendergaard, M. (2019). Ovarian Cancer Targeting Phage for In Vivo Near-Infrared Optical Imaging. Diagnostics, 9, 183.
Newton-Northup, J.R., and Deutscher, S.L. (2017). Bacteriophage for the Development of Novel Tumor-Targeting Agents with Specific Pharmacokinetics and Imaging Applications. Methods in Molecular Biology in Biosensors and Biodetection.
Newton-Northup, J.R., and Deutscher, S.L.. (2016). Cytotoxic Tumor-Targeting Peptides From In Vivo Phage Display. Combinatorial Chemistry & High Throughput Screening. Vol. 19(5): 370–377
García, M. F., Zhang, X., Shah, M., Newton-Northup, J., Cabral, P., Cerecetto, H., and Quinn, T. (2016). 99mTc-bioorthogonal click chemistry reagent for in vivo pretargeted imaging. Bioorganic & Medicinal Chemistry. Vol. 24(6): 1209–1215
Newton-Northup, J.R., Dickerson, M.T., Kumar, S.R., Smith, G.P., Quinn, T.P., And Deutscher, S.L. (2014) In vivo bacteriophage peptide display to tailor pharmacokinetics of biological nanoparticles. Molecular Imaging and Biology. 16(6), 854-864.
Soendergaard M., Newton-Northup J. R., Deutscher S. L. (2014): In Vivo Phage Display Selection of an Ovarian Cancer Targeting Peptide for SPECT/CT Imaging. American Journal of Nuclear Medicine and Molecular Imaging. 4(6): 561–570.
Soendergaard, M., Newton-Northup, J.R., and Deutscher, S.L. (2014) In vitro high throughput phage display selection of ovarian cancer avid phage clones for near-infrared optical imaging. Combinatorial Chemistry and High Throughput Screening. 17(10).
Newton-Northup, J.R., and Deutscher, S.L. (2013). Contending With Target Unrelated Peptides from Phage Display. Journal of Molecular Imaging & Dynamics. Vol. 2(2):
Newton-Northup, J. R., Dickerson, M. T., Ma, L., Besch-Williford, C. L., Deutscher, S. L. (2013). Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide. Clinical & Experimental Metastasis. Vol. 30:119–132
Newton-Northup, J.R., and Deutscher, S.L. (2012) Contending with target unrelated peptides from phage display. Journal of Molecular Imaging and Dynamics. 2(2).
Soendergaard, M., Newton-Northup, J.R., Palmier, M.O., and Deutscher, S.L. (2011) Peptide phage display for discovery of novel biomarkers for imaging and therapy of cell subpopulations in ovarian cancer. Journal of Molecular Biomarkers and Diagnosis, S:2.
Newton-Northup, J.R., Figueroa, S.D., and Deutscher, S.L. (2010). Streamlined in vivo selection and screening of human prostate carcinoma avid phage particles for development of peptide based in vivo tumor imaging agents. Combinatorial chemistry & high throughput screening. 14(1):9-21
Deutscher, S. L., Dickerson, M., Gui, G., Newton, J., Holm, J. E., Vogeltanz-Holm, N., Kliethermes, B., Hewett, J. E., Kumar, S. R., Quinn, T. P., Sauter, E. R. (2010). Carbohydrate antigens in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy. BMC Cancer. Vol. 10(519)
Newton-Northup, J.R., Figueroa, S.D., Quinn, T. P., and Deutscher, S.L. (2009). Bifunctional phage-based pretargeted imaging of human prostate carcinoma. Nuclear Medicine and Biology. Vol. 36(7):789-800
Jin, X., Newton, J. R., Montgomery, S., Smith, G. P. (2009). A generalized kinetic model for amine modification of proteins with application to phage display. Biotechniques. Vol. 46(3):175-182
Newton-Northup, J.R., and Deutscher, S.L. (2009). In vivo bacteriophage display for the discovery of novel peptide-based tumor-targeting agents. Methods in Molecular Biology. Vol. 504:275-90.
Newton-Northup, J.R., and Deutscher, S.L. (2008). Peptide Phage Display. Handbook of Experimental Pharmacology: Molecular Imaging I. Vol. 185 Pt 2:145-163.
Newton, J. R., Miao, Yubin., Deutscher, S. L., and Quinn, T. P. (2007). Melanoma Imaging with Pretargeted Bivalent Bacteriophage. Journal of Nuclear Medicine. Vol. 48(3):429-436
Newton, J. R., Kelly, K. A., Mahmood, U., Weissleder, R., and Deutscher, S. L. (2006) In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. Neoplasia. 8(9), 772-780.